Identification and Validation of Established and Novel Biomarkers for Infections in Burns
Technical Report,30 Sep 2016,29 Sep 2017
The University of Texas Medical Branch at Galveston Galveston United States
Pagination or Media Count:
Hypothesis Plasma proteins, clinical data, and patient characteristics can be used to prospectively identify severely burned patients who are at risk for developing sepsis and other infections. Measurement of already identified biomarkers alongside novel biomarkers identified with discovery proteomics can improve identification of risk for infection and identify the early stages of infection prior to clinical detection. This multicenter study will enable us to identify novel biomarkers, validate whether the already identified biomarkers are appropriate, and establish a predictive model. Rationale Our prior work has shown that severely burned patients who die from sepsis can be identified via their serum protein expression profile at the time of admission, that in the days prior to septic death there is an increase in serum biomarker expression, and that the use of both clinical and proteomic information as biomarkers improves the accuracy of patient survival prediction. Others have shown that procalcitonin is a good candidate marker of sepsis in burn patients. Clinical indices such as heart rate, mean arterial pressure, base deficit, temperature, and glucose levels more accurately identify sepsis in the burn patients than does the ABA consensus definition. Methods 200 patients will be enrolled at four sites within the Burns Research in Texas Consortia. Blood samples will be taken daily, and clinical data recorded.
- Stress Physiology
- Medicine and Medical Research